The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASTRO 2022 | The impact of stereotactic body radiation therapy on outcomes in NSCLC
Kevin Stephans, MD, Cleveland Clinic, Cleveland, OH, discusses the impact of stereotactic body radiation therapy (SBRT) dose on outcomes in non-small cell lung cancer (NSCLC), with consideration to tumour histology. Dr Stephans also discusses possible risk factors for disease recurrence. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
